通心络胶囊与阿托伐他汀对PCI术后支架内再狭窄与炎症因子的协同干预作用研究

The Influence of Tongxinluo Capsule and Atorvastatin on In-stent Restenosis and Inflammatory Factors after Percutaneous Coronary Intervention

目的探讨通心络胶囊联合阿托伐他汀对经皮冠状动脉介入治疗(PCI)术后支架内再狭窄(ISR)与炎症因子的影响。方法收集156例行PCI术病人,随机均分为3组。对照组给予阿司匹林联合氯吡格雷治疗;试验A组在对照组基础上加用阿托伐他汀治疗;试验B组在试验A组基础上加用通心络胶囊治疗,各组均连续用药6个月,每月定期随访记录其主要不良心血管事件(MACE),并检测各组治疗前后血清炎症因子高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)水平。结果治疗6个月后,试验A组、试验B组病人ISR与MACE发生率及炎症因子hs-CRP、IL-6、TNF-α水平均显著低于对照组(P<0.05),且试验B组显著低于试验A组(P<0.05)。结论通心络胶囊可协同阿托伐他汀在常规治疗基础上显著降低ISR、MACE发生率与术后炎症因子水平。

Objective To investigate the effect of Tongxinluo capsule（TXLC） combined with atorvastatin on in stent restenosis （SR） and inflammatory factors after percutaneous coronary intervention （PCI） .Methods One hundred and fifty six patients after PCI was chosen as the research objects and randomly divided into control group treated with aspirin and clopidogrel,group A treated with as-pirin, clopidogrel and atorvastatin,group B treated with aspirin,clopidogrel,atorvastatin,TXLC for 6 months with monthly follow - ups. The recurrence of major adverse cardiovascular events （MACE） were recorded.The incidence of ISR and MACE,the levels of serum high sensitivity C reactive protein（hs CRP）, interleukin（IL） 6,and tumor necrosis factor（TNF） a were observed before and af-ter treatment-Results After 6 months of treatment,the incidence of ISR and MACE,the levels of serum hs CRP, IL 6,and TNF a in group A and group B were were significantly lower than those in control group （ P 〈0.05）, which was lower in group B than those in group A （ P 〈0.05） .Conclusion On the basis of routine antiplatelet therapy,TXLC and atorvastatin can significantly reduce the in-cidence of ISR and MACE and the inflammatory factors levels.